GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting
20 Marzo 2024 - 11:30AM
Business Wire
- 81.4% of the Company’s share capital was represented at the
EGM and resolutions were all unanimously approved
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a
biopharmaceutical company developing treatments for
neurodegenerative and autoimmune diseases, such as multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe
neuropsychiatric consequences of COVID-19 (post-COVID or
Long-COVID), today announced that its shareholders have approved
all resolutions proposed at its Extraordinary General Meeting (EGM)
of March 18, 2024. These included among others:
- Election of two new Members of the Board of Directors, Mrs
Sandrine Flory, Chief Financial Officer of Institut Mérieux, and Mr
Pascal Lemaire, Chief Financial Officer of Servier
- Introduction of a variable compensation for the Board of
Directors for 2023-2024, allowing to award stock options in
exchange for a reduction of the fixed compensation
- Increase of the capital band and of the conditional capital, to
replenish these provisions following the February 2024 capital
increase.
81.42% of the Company’s share capital was represented at the AGM
and resolutions were all unanimously approved. Detailed results
will be available on the Company’s website at:
http://www.geneuro.com/en/investors/general-meetings.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It has rights to 18 patent families
protecting its technology.
For more information, visit: www.geneuro.com
Disclaimer:
This press release contains certain forward - looking statements
and estimates concerning GeNeuro’s financial condition, operating
results, strategy, projects and future performance and the markets
in which it operates. Such forward-looking statements and estimates
may be identified by words, such as “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “intend,” “is designed to,” “may,”
“might,” “plan,” “potential,” “predict,” “objective,” “should,” or
the negative of these and similar expressions. They incorporate all
topics that are not historical facts. Forward looking statements,
forecasts and estimates are based on management’s current
assumptions and assessment of risks, uncertainties and other
factors, known and unknown, which were deemed to be reasonable at
the time they were made but which may turn out to be incorrect.
Events and outcomes are difficult to predict and depend on factors
beyond the company’s control. Consequently, the actual results,
financial condition, performances and/or achievements of GeNeuro or
of the industry may turn out to differ materially from the future
results, performances or achievements expressed or implied by these
statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of
these forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates
speak only as of the date on which they are made, and GeNeuro
undertakes no obligation to update or revise any of them, whether
as a result of new information, future events or otherwise, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240320180393/en/
GeNeuro
Jesús Martin-Garcia Chairman and CEO +41 22 552 48 00
investors@geneuro.com
NewCap (France)
Louis-Victor Delouvrier / Mathilde Bohin (investors) +33 1 44 71
98 52 Arthur Rouillé (media) +33 1 44 71 00 15
geneuro@newcap.eu
GeNeuro (EU:GNRO)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
GeNeuro (EU:GNRO)
Gráfica de Acción Histórica
De May 2023 a May 2024